A randomized control trial exploring the remedial eradiracation efficacy in the patients with helicobater pylori infection treated with the minocycline-containing quadruple and tailored therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003975

Enrollment

Unknown

Registered

2013-12-10

Start date

2014-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Quadruple regimen:minocycline-containing quadruple therapy

Individualization:Individualization therapy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Consecutive patients for upper endoscopy with various symptoms; 2. HP RUT positive; 3. Aged 18 to 70 years, man or woman; 4. Once failure for H. pylori eradication.

Exclusion criteria

Exclusion criteria: 1. Taking any drug which could influence the study results such as PPI, H2-receptor blockers, bismuth salts and antibiotics in the previous 4 weeks; 2. Gastrointestinal malignancy; 3. Previous gastric and esophageal surgeries; 4. Zollinger-Ellison syndrome; 5. Severe concomitant cardiovascular, respiratory, hematological, renal, hepatic, neurological, psychiatric or endocrine diseases; 6. History of allergy to any of the drugs used in the study; 7. Pregnancy or lactation; 8. Alcohol abuse; 9. Any other clinically significant medical condition that could increase risk of side effects.

Design outcomes

Primary

Measure	Time frame
Eradication rate;	—

Secondary

Measure	Time frame
Adverse event rate;Compliance;	—

Countries

China

Contacts

Public ContactLiya Zhou

Peking University Third Hospital

liyazhou@medmail.com.cn+86 15611908239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026